A Phase 1/1b Study of IAM1363 in HER2 Cancers
Iambic Therapeutics, Inc
Iambic Therapeutics, Inc
National Cancer Institute (NCI)
Stemline Therapeutics, Inc.
Wake Forest University Health Sciences
NRG Oncology
Mayo Clinic
Institut Cancerologie de l'Ouest
Weill Medical College of Cornell University
InSightec
Brigham and Women's Hospital
M.D. Anderson Cancer Center
MedSIR
MedSIR
Yale University
Hoffmann-La Roche
Baptist Health South Florida
UMC Utrecht
Thomas Jefferson University
City of Hope Medical Center
Roswell Park Cancer Institute
AstraZeneca
Sapience Therapeutics
Barbara Ann Karmanos Cancer Institute
Adela, Inc
Hoosier Cancer Research Network
Stanford University
Sunnybrook Health Sciences Centre
University of Rochester
Mayo Clinic
AstraZeneca
H. Lee Moffitt Cancer Center and Research Institute
Beijing Biostar Pharmaceuticals Co., Ltd.
Peking University Cancer Hospital & Institute
Weill Medical College of Cornell University
UNC Lineberger Comprehensive Cancer Center
Novartis
SWOG Cancer Research Network
Virginia Commonwealth University
AVM Biotechnology Inc
Maastricht Radiation Oncology
Peking University Cancer Hospital & Institute
Hellenic Cooperative Oncology Group
Washington University School of Medicine
Jonsson Comprehensive Cancer Center
MedSIR
NRG Oncology
Mayo Clinic
Biogen
Columbia University
Tempus AI